以下是采访提纲，采访内容稍后呈上

LG Mellbin 瑞典斯德哥尔摩心脏协会

Cardiology Unit， Institution of Medicine， Karolinska Institutet， Sweden

 International Circulation:  BARI 2D is a landmark study， the first time to focus on patients with diabetes and heart disease. How do you assess it’s value?

Linda Mellbin:  I think it is a very important study.  It is the first time if you consider the revascularization part， but it is not the first study to focus on diabetes and cardiovascular disease.  The study has two parts， the revascularization portion and the glucose monitoring portion.

International Circulation:   BARI 2D study shows that intensive medical therapy based on prompt revascularization therapy has no advantage in reducing the main composite endpoint events (death or major cardiovascular events)， what do you think about the result?

Linda Mellbin:  It is very interesting to see that.  We can do a lot of good with medical treatment as well as a lot of good with lifestyle interventions.  But if you look in subgroup populations in the trial， you can see that CABG is superior in certain cases.  But， of course， it is good for us to know that we can do something with lifestyle and medications as well， in addition to surgical interventions.